Skip to main content
. 2017 Feb 17;11(3):320–334. doi: 10.1002/1878-0261.12039

Figure 6.

Figure 6

Dual inhibition of Akt and c‐Met as a second‐line therapy suppresses sorafenib‐resistant HCC tumors. (A) Animal experimental schedule was described in Materials and Methods. (B) The size (mm3) of tumors was recorded. Tumors harvested at the end of experiments were weighed (C) and photographed (D). (E) The bodyweights of mice were monitored ‘**’ (P < 0.001) indicates a significant difference.